Showing 4001-4010 of 7034 results for "".
- Can Blocking the Function of the CCR6 Chemokine Help Treat Psoriasis and Psoriatic Arthritis?https://practicaldermatology.com/news/can-blocking-the-function-of-the-ccr6-chemokine-help-treat-psoriasis-and-psoriatic-arthritis/2460825/A novel chemical blocker targeting chemokine proteins may significantly reduce skin and joint inflammation in psoriasis and psoriatic arthritis, according to a study in mice. Chemokines are small molecules with a critical role in the body’s response to inflammation and infection.
- Parents Magazine Announces Winners of Best Skin Care for Kids 2021https://practicaldermatology.com/news/parents-magazine-announces-winners-of-best-skin-care-for-kids-2021/2460823/Meredith Corporation's Parents magazine released this year's Best Skin Care for Kids. Parents experts thoroughly tested nearly 300 formulas of parent recommendations, brand best-sellers, and new releases for skin and hair with 55 families. A total of 30 products that are a
- AstraZeneca's Anifrolumab Shows Benefit for Skin, Joint Symptoms of Lupushttps://practicaldermatology.com/news/astrazenecas-anifrolumab-shows-benefit-for-skin-joint-symptoms-of-lupus/2460819/Anifrolumab is consistently associated with improvements in both skin rash and arthritis across three different disease measures in patients with moderate to severe systemic lupus erythematosus (SLE), results of a new post-hoc analysis of pooled data from the TULIP phase 3 clinical trials show. T
- BioFactura Starts Phase I Study of BFI-751, a Stelara Biosimilarhttps://practicaldermatology.com/news/biofactura-starts-phase-i-study-of-bfi-751-a-stelara-biosimilar/2460811/BioFactura is set to begin a pivotal pharmacokinetics Phase 1 clinical trial for its Ustekinumab biosimilar BFI-751. The first-in-human Phase I study will assess the effects on healthy human volunteers compared to the biologic medicine, Stelara. This is the first time BFI-751 has been a
- It's Back: BTL's National Emsculpt Week is Cominghttps://practicaldermatology.com/news/its-back-btls-national-emsculpt-week-is-coming/2460804/BTL Aesthetics is bringing back National Emsculpt Week. This holiday was added to the official National Day
- HydraFacial and Vesper Healthcare Announce Closing of Business Combination, Combined Company Now Known as The Beauty Health Companyhttps://practicaldermatology.com/news/hydrafacial-and-vesper-healthcare-announce-close-business-combination-combined-company-now-known-as-the-beauty-health-company/2460800/It's officially official: Vesper Healthcare and The HydraFacial Company closed their previously announced business combination. The combined company will be known as The Beauty Health Company. The business combination was approved by Vesper Healthcare’s st
- UCB: Bimekizumab PDUFA Date Set for Octoberhttps://practicaldermatology.com/news/ucb-bimekizumab-pdufa-set-for-october/2460787/The FDA's Prescription Drug User Fee Act (PDUFA) date for UCB’s Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis is October 15, 2021, UCB has indicated. In a
- Pulse Biosciences Survey: Clearing Pigmented Lesions is No. 1 Priority for Manyhttps://practicaldermatology.com/news/pulse-biosciences-survey-clearing-pigmented-lesions-is-no-1-priority-for-many/2460786/A majority of patients with unwanted benign lesions are interested in a new procedure to clear these lesions, according to a new survey by Pulse Biosciences that was presented at the American Academy of Dermatology (AAD) Virtual Annual Meeting. A diverse sample of 405 aesthetic patients
- AAD Survey: One-Third of Americans Flunk Basic Quiz on Skin Cancer and Sun Exposurehttps://practicaldermatology.com/news/aad-survey-one-third-of-americans-flunk-basic-quiz-on-skin-cancer-and-sun-exposure/2460785/One-third of Americans lack a basic understanding of skin cancer and sun protection, according to a recent survey of 1,000 U.S. adults from the American Academy of Dermatology. Shockingly, more than half (53%) of adults are unaware that shade can protect them from the sun’s harmfu
- Data Show Amgen's Otezla Benefits Patients with Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/data-show-amgens-otezla-benefits-patients-with-mild-to-moderate-psoriasis/2460775/Amgen’s Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) involvement, according to findings from the placebo-controlled, phase 3 ADVANCE trial, presented at the AAD VMX 2021